Group 1 - The vitamin sector experienced a decline of 0.39%, ranking among the top losers in the concept sector, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the daily limit down [1][2] - Notable gainers in the vitamin sector included Haiwang Biological, *ST Zhongji, and Zhenhua Co., which rose by 10.03%, 5.01%, and 4.99% respectively [1][4] - The vitamin sector saw a net outflow of 706 million yuan from major funds, with 43 stocks experiencing net outflows, and 10 stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was Zhongsheng Pharmaceutical, with a net outflow of 684 million yuan, followed by Xinhua Pharmaceutical and Guangji Pharmaceutical with net outflows of 58.33 million yuan and 50.49 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Haiwang Biological, Zhenhua Co., and Xinhecheng, with net inflows of 145 million yuan, 67.37 million yuan, and 24.76 million yuan respectively [2][4] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78% despite a price drop of 10% [3][4]

Core Viewpoint - Haiwang Biological experienced a significant increase in stock price, reaching the daily limit with a turnover rate of 15.64% and a transaction volume of 1.333 billion yuan, indicating strong market interest and activity [2]. Trading Activity - The stock was listed on the Shenzhen Stock Exchange due to a price deviation of 9.04%, with institutional investors net selling 22.34 million yuan while the Shenzhen Stock Connect saw a net purchase of 4.42 million yuan [2]. - The top five trading departments accounted for a total transaction volume of 282 million yuan, with net buying amounting to 72.87 million yuan [2]. - The main funds saw a net inflow of 145 million yuan, with large orders contributing 187 million yuan to the inflow, while large orders experienced a net outflow of 42.12 million yuan over the day [2]. Margin Trading Data - As of November 27, the margin trading balance for the stock was 203 million yuan, with a financing balance of 202 million yuan and a securities lending balance of 564,500 yuan [3]. - Over the past five days, the financing balance increased by 25.25 million yuan, reflecting a growth rate of 14.28%, while the securities lending balance rose by 30,940 yuan, marking a significant increase of 121.29% [3]. Major Trading Departments - The top buying departments included Guotai Junan Securities with a purchase of 45.45 million yuan and the Shenzhen Stock Connect with 42.55 million yuan [3]. - The selling departments were led by the Shenzhen Stock Connect, which sold 38.13 million yuan, followed by institutional specialized seats with significant sell amounts [4].

Market Overview - The Shanghai Composite Index rose by 0.34% on November 28, with 29 out of 31 sectors experiencing gains, led by the steel and agriculture sectors, both up by 1.59% [1] - The pharmaceutical and biological industry saw a modest increase of 0.14% [1] - The banking and coal sectors faced declines, down by 0.83% and 0.14% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets reached 10.84 billion yuan, with 19 sectors experiencing net inflows [1] - The electronics sector led the net inflow with 3.423 billion yuan and a daily increase of 1.30% [1] - The non-ferrous metals sector followed with a net inflow of 3.051 billion yuan and a daily increase of 1.44% [1] - Conversely, 12 sectors experienced net outflows, with the pharmaceutical and biological sector seeing the largest outflow of 2.334 billion yuan [1] Pharmaceutical and Biological Sector Performance - Within the pharmaceutical and biological sector, 477 stocks were tracked, with 260 stocks rising and 201 stocks falling [2] - The top three stocks with the highest net inflow were Haiwang Biological (1.45 billion yuan), Baihua Pharmaceutical (977.51 million yuan), and Tailong Pharmaceutical (801.56 million yuan) [2] - The sector's outflow was dominated by Zhongsheng Pharmaceutical (6.84 billion yuan), WuXi AppTec (1.65 billion yuan), and Te Yi Pharmaceutical (1.12 billion yuan) [2] Top Gainers in Pharmaceutical Sector - Haiwang Biological saw a significant increase of 10.03% with a turnover rate of 15.64% and a net inflow of 145.23 million yuan [4] - Baihua Pharmaceutical increased by 10.01% with a net inflow of 97.75 million yuan [4] - Tailong Pharmaceutical rose by 5.37% with a net inflow of 80.16 million yuan [4] Top Losers in Pharmaceutical Sector - Zhongsheng Pharmaceutical experienced a decline of 10.00% with a net outflow of 683.65 million yuan [4] - WuXi AppTec fell by 1.10% with a net outflow of 164.72 million yuan [4] - Te Yi Pharmaceutical decreased by 6.41% with a net outflow of 112.06 million yuan [4]

Group 1 - The flu concept sector declined by 0.49%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the flu concept sector that saw significant declines include Zhongsheng Pharmaceutical (-10.00%), Guangji Pharmaceutical (-9.98%), and Hainan Haiyao (+2.34%) [2][3] - The flu concept sector experienced a net outflow of 1.24 billion yuan, with Zhongsheng Pharmaceutical leading the outflow at 684 million yuan [2][3] Group 2 - The top gainers in the flu concept sector included Haiwang Biological (+10.03%), Baihua Pharmaceutical (+10.01%), and Tailong Pharmaceutical (+5.37%) [1][7] - The overall market saw a mixed performance, with 63 stocks in the flu concept sector rising while others fell significantly [1][2] - The concept sectors with the highest gains included Titanium Dioxide (+4.31%) and Hainan Free Trade Zone (+3.54%), contrasting with the flu concept sector's decline [2]

从资金流向上来看，当日医药商业板块主力资金净流出2.28亿元，游资资金净流出2472.38万元，散户资 金净流入2.52亿元。医药商业板块个股资金流向见下表： 证券之星消息，11月28日医药商业板块较上一交易日上涨0.29%，海王生物领涨。当日上证指数报收于 3888.6，上涨0.34%。深证成指报收于12984.08，上涨0.85%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000078 | 海壬生物 | 3.40 | 10.03% | 410.67万 | 13.33 Z | | 603122 | 合富中国 | 23.82 | 7.49% | 108.60万 | 24.53亿 | | 600538 | 国发股份 | 6.45 | 2.06% | 14.97万 | 9550.39万 | | 301126 | 达嘉维康 | 12.83 | 0.94% | 11.65万 | 1.50亿 | | 000411 | 英特集团 | 12.04 | 0.92% | 13. ...

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 买方营业部 (万元) | 卖方营业部 | | | 2025-11-28 | 000078 | 海王生物 | 3.40 | 30.00 | 102.00 国泰海通证券股份 有限公司深圳福华 三路证券营业部 | 机构专用 | | 11月28日，海王生物大宗交易成交30万股，成交额102万元，占当日总成交额的0.08%，成交价3.4元， 较市场收盘价3.4元持平。 ...

据天眼查APP显示，深圳市海王生物工程股份有限公司成立于1992年12月13日，注册资本263112.3257 万人民币。（数据宝） （文章来源：证券时报网） 数据宝统计，截至11:12，海王生物成交额12.86亿元，创2020年3月11日以来新高。最新股价上涨 10.03%，换手率15.12%。上一交易日该股全天成交额为12.45亿元。 ...

Core Points - The stock of Haiwang Biological has reached a trading limit, marking three consecutive days of limit-up, with a current price of 3.40 yuan and a trading volume of 2.86 billion shares, resulting in a total transaction amount of 9.12 billion yuan [2] - During the consecutive limit-up period, the stock has increased by 33.33%, with a cumulative turnover rate of 30.09% [2] - The latest total market capitalization of the A-shares is 8.946 billion yuan, with a circulating market capitalization of 8.930 billion yuan [2] Financing Data - As of November 27, the margin trading balance for the stock is 203 million yuan, with a financing balance of 202 million yuan, reflecting an increase of 5.27 million yuan from the previous trading day, a growth of 2.68% [2] - Over the past three days, the financing balance has increased by 26.38 million yuan, representing a growth of 15.01% [2] Trading Activity - The stock has appeared on the Dragon and Tiger list due to a cumulative price deviation of 20% over three trading days and a daily price deviation of 7%, with institutional net purchases amounting to 28.19 million yuan and a cumulative net sale of 30.07 million yuan by the Shenzhen Stock Connect [2] - The trading performance over recent days shows fluctuations in daily price changes and turnover rates, with notable net inflows and outflows of capital [3] Financial Performance - For the first three quarters, the company reported a total operating income of 21.513 billion yuan, a year-on-year decrease of 12.38%, and a net profit of 25.703 million yuan, down 44.39% year-on-year [2] - The basic earnings per share are reported at 0.0098 yuan, with a weighted average return on net assets of 1.42% [2]

Core Viewpoint - Haiwang Bio has experienced a significant stock price increase, achieving a three-day cumulative rise of 33.33% and hitting the daily limit on November 28 [2]. Company Summary - Haiwang Bio's stock has shown strong performance with a consecutive three-day limit-up, indicating positive market sentiment and potential investor interest [2].

深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）股票价格于2025年11月26日至2025年 11月27日连续两个交易日收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》的相关 规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票异常波动，经公司对有关事项核查，并向公司控股股东及实际控制人发函核实，现将有关 情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息。 3、近期公司生产经营情况正常，公司经营情况及内外部经营环境未发生重 大变化。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 三、应披露而未披露的重大信息的说明 本公司董事局确认，本公司目前没有任何根据《深圳证券交易所股票上市规则》等有关规定应予以披露 而未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董事局也未获悉本公司有根据《深圳证 券交易所股票上市规则》等 ...